SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased social activity and trading volume as investors discuss its technical strengths, including post-quantum security and real-world asset (RWA) potential. The community is actively debating the impact of recent leadership changes and the broader market's anticipation of upcoming regulatory clarity.

Maul Coin

Maul Coin is generating buzz as an early-stage community-driven project, with supporters actively rallying to increase its holder count and social media presence in hopes of driving a significant market cap expansion. The community is focused on organic growth and transparency, eagerly awaiting official charting status while coordinating promotional efforts across various platforms to maintain momentum.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is trending as investors debate its long-term potential following a steep post-launch decline, with the community split between those accumulating at current price levels and others concerned about future token dilution. Supporters are actively discussing the project's high staking rewards and parallel processing technology as indicators of future value, while critics highlight low network activity and a challenging broader crypto market environment.

GraniteShares ETF Trust - GraniteShares 2x Long COIN Daily ETF

GraniteShares 2x Long COIN Daily ETF

CONL is trending as the community closely monitors the upcoming Senate Banking Committee markup of the CLARITY Act, viewing potential regulatory progress as a major catalyst for Coinbase and the broader crypto sector. Investors are also actively debating its long-term viability, with many using the stock's recent volatility to accumulate positions in anticipation of a potential rebound linked to Coinbase's earnings and Bitcoin's price trajectory.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is generating community buzz due to its ultra-low circulating supply and small market cap, which investors believe make it primed for significant price volatility and potential gains. Discussions are heavily focused on the hope for a resurgence in the NFT market, new exchange listings, and the token's historical ability to move rapidly with even minor increases in trading volume.

The ArcBlock project was created to create the first Blockchain ecosystem in the world. Develop and develop decentralized applications (DApp) according to objectives. ArcBlock, one of the ICO projects emerging in early 2018. Just launched on 3/1/2018, ArcBlock has quickly attracted the attention of technology as well as investors. ArcBlock brings great technological advancements that will open the third generation of blockchain applications.  Arcblock work by bridging the gap between different blockchains and their respective ecosystems has not been easy. There are some solutions which attempt to solve this problem, but it is evident there is plenty of room for competition in this regard. Building an open chain access layer capable of spanning multiple new and existing blockchains is a very interesting business model.  Building a new ecosystem meant to connect various chains will not be easy. As of right now, the team has completed its token sale, and the first public release candidate for the Open Chain Access Protocol will be released in Q3. Early 2019 will herald the introduction of more technical features and an Ethereum Blocklet prototype.

ArcBlock (ABT) is seeing heightened market activity and increased trading volume as community members speculate on potential AI integration and exchange listings, sparking both bullish price targets and skepticism regarding the project's utility. Conversations are dominated by long-term holders debating the legitimacy of recent partnership announcements and the token's ability to sustain upward momentum amid ongoing volatility.

EyePoint Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Inc.

EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals is currently experiencing significant market attention, driven by institutional accumulation and investor anticipation regarding pivotal Phase 3 trial data for Duravyu. The community is actively debating the company's competitive positioning, specifically evaluating its Duravyu candidate against rival TKI treatments in the wet AMD and DME markets, while monitoring ongoing legal developments and management's strategic communication.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

The Zebec Network (ZBCN) community is actively debating the project's long-term utility versus its recent price performance, with many holders focusing on institutional partnerships and the potential for a breakout following the conclusion of token unlocks. While skeptics highlight the high circulating supply and recent downward trends, advocates remain bullish on the network's integration into payroll systems and anticipated announcements at industry events.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

Structure Therapeutics ($GPCR) is trending sharply following positive Phase 2b clinical data for its oral GLP-1 drug, aleniglipron, which showed weight loss results that have fueled intense speculation regarding the company as a prime M&A target. Investors are actively debating the drug's efficacy and tolerability profile compared to competitors like Viking Therapeutics ($VKTX), with the community closely analyzing management's communication style and potential buyout interest from big pharma.

ETF Series Solutions - ESS U.S.Global Jets ETF

US Global Jets ETF

The US Global Jets ETF (JETS) is trending as investors grapple with significant volatility in the airline sector, driven by a convergence of rising jet fuel costs, operational disruptions from severe weather, and high-profile safety concerns affecting major carriers. Community members are actively debating the long-term viability of airline stocks, weighing record travel demand and TSA throughput against concerns over debt levels, industry-wide labor costs, and potential economic headwinds impacting consumer discretionary spending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading Down 1.3%  - Should You Sell?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Stock Price Down 1.3% - Should You Sell...

BridgeBio Oncology (BBOT) Spotlights Next-Gen RAS Pipeline, $425M Cash Runway Into 2028

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) used a presentation at Leerink Partners' Global Healthcare Conference to outline its strategy around next-generation RAS therapeutics, highlighting three...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Issues Quarterly Earnings Results

BridgeBio Oncology Therapeutics (NASDAQ:BBOT - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.49) EPS for the quarter, topping analysts' consensus...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Shares Gap Up After Better-Than-Expected Earnings

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Shares Gap Up Following Better-Than-Expected Earnings...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Price Target Raised to $29.00 at HC Wainwright

HC Wainwright lifted their price target on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a "buy" rating in a report on Friday...

BridgeBio Oncology Touts Best in RAS Pipeline, Highlights BBO-8520 Response and Combo Tolerability

Executives from BridgeBio Oncology Therapeutics (NASDAQ:BBOT) outlined the company's strategy to build what they call the Best in RAS pipeline during an Oppenheimer-hosted discussion, emphasizing...

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Shares Up 11.3% - Still a Buy?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Trading 11.3% Higher - What's Next...

Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. The company was founded on August 1, 2016 and is headquartered in South San Francisco, CA.

BridgeBio Oncology Therapeutics Inc.

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.52	--	--	N/A
Q4 '25	-$0.63	-$0.49	22.60%	BEAT
Q3 '25	-$0.38	-$1.03	-169.87%	MISSED
Q2 '25	-$38.51	-$49.62	-28.84%	MISSED

BBOT
BridgeBio Oncology Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest BBOT News

BBOTBridgeBio Oncology Therapeutics Inc.